“…Use of regimens with low evidence of benefit, such as CHOP, CVP or chlorambucil monotherapy, was observed in a significant proportion of patients (45%).Finally, the registry is also intended to promote greater scientific integration. The Brazilian Group of CLL (GBLLC) was created in 2013, with periodic meetings, recruitment for clinical trials and publication of recommendations for CLL diagnosis and treatment 8. Cooperative efforts in Brazil and other developing countries are in need for a more representative scenario of CLL, and the adequate assessment of epidemiology, outcomes and unmet needs in diagnosis, prognostic evaluation and treatment.…”